Cargando…

Efficacy and safety of pharmacological treatments for Lyme neuroborreliosis in children: a systematic review

BACKGROUND: Many aspects of pharmacological treatment of Lyme neuroborreliosis in children, such as choice of drug, dosage, and duration are subject to intense debates, leading to uncertainties in patients’ parents and healthcare providers alike. To assess the available evidence for pharmacological...

Descripción completa

Detalles Bibliográficos
Autores principales: Dersch, Rick, Hottenrott, Tilman, Schmidt, Stefanie, Sommer, Harriet, Huppertz, Hans-Iko, Rauer, Sebastian, Meerpohl, Joerg J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5043629/
https://www.ncbi.nlm.nih.gov/pubmed/27686962
http://dx.doi.org/10.1186/s12883-016-0708-y
_version_ 1782456790970007552
author Dersch, Rick
Hottenrott, Tilman
Schmidt, Stefanie
Sommer, Harriet
Huppertz, Hans-Iko
Rauer, Sebastian
Meerpohl, Joerg J.
author_facet Dersch, Rick
Hottenrott, Tilman
Schmidt, Stefanie
Sommer, Harriet
Huppertz, Hans-Iko
Rauer, Sebastian
Meerpohl, Joerg J.
author_sort Dersch, Rick
collection PubMed
description BACKGROUND: Many aspects of pharmacological treatment of Lyme neuroborreliosis in children, such as choice of drug, dosage, and duration are subject to intense debates, leading to uncertainties in patients’ parents and healthcare providers alike. To assess the available evidence for pharmacological treatment for children with Lyme neuroborreliosis we conducted a systematic review. METHODS: The comprehensive systematic literature search included randomized-controlled trials (RCTs) and non-randomized studies (NRS) on treatment of Lyme neuroborreliosis in children (age <18 years). Our primary outcome was neurological symptoms after treatment. Risk of bias was assessed with the Cochrane risk of bias tools for RCTs and NRS. Quality of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. RESULTS: Two RCTs and four NRS were eligible for inclusion. Risk of bias in RCTs and NRS was generally high. Reporting of studies was generally poor. Regarding the primary outcome neurological symptoms at 1–3 months, no statistically significant difference could be found in cohort studies between doxycycline and beta-lactam antibiotics. In two RCTs comparing penicillin G and ceftriaxone, no patient experienced residual neurological symptoms at the last reported time points. Quality of evidence according to GRADE was judged very low. CONCLUSIONS: Data is scarce and with limited quality. Several issues could not be addressed due to scarcity of information. No eligible study compared different treatment durations. According to the available evidence, there seems to be no difference between different antibiotic agents for the treatment of Lyme neuroborreliosis in children regarding neurological symptoms. We found no evidence that supports extended antibiotic regimes. REVIEW REGISTRATION: Systematic review registration: CRD42014008839. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12883-016-0708-y) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5043629
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-50436292016-10-05 Efficacy and safety of pharmacological treatments for Lyme neuroborreliosis in children: a systematic review Dersch, Rick Hottenrott, Tilman Schmidt, Stefanie Sommer, Harriet Huppertz, Hans-Iko Rauer, Sebastian Meerpohl, Joerg J. BMC Neurol Research Article BACKGROUND: Many aspects of pharmacological treatment of Lyme neuroborreliosis in children, such as choice of drug, dosage, and duration are subject to intense debates, leading to uncertainties in patients’ parents and healthcare providers alike. To assess the available evidence for pharmacological treatment for children with Lyme neuroborreliosis we conducted a systematic review. METHODS: The comprehensive systematic literature search included randomized-controlled trials (RCTs) and non-randomized studies (NRS) on treatment of Lyme neuroborreliosis in children (age <18 years). Our primary outcome was neurological symptoms after treatment. Risk of bias was assessed with the Cochrane risk of bias tools for RCTs and NRS. Quality of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. RESULTS: Two RCTs and four NRS were eligible for inclusion. Risk of bias in RCTs and NRS was generally high. Reporting of studies was generally poor. Regarding the primary outcome neurological symptoms at 1–3 months, no statistically significant difference could be found in cohort studies between doxycycline and beta-lactam antibiotics. In two RCTs comparing penicillin G and ceftriaxone, no patient experienced residual neurological symptoms at the last reported time points. Quality of evidence according to GRADE was judged very low. CONCLUSIONS: Data is scarce and with limited quality. Several issues could not be addressed due to scarcity of information. No eligible study compared different treatment durations. According to the available evidence, there seems to be no difference between different antibiotic agents for the treatment of Lyme neuroborreliosis in children regarding neurological symptoms. We found no evidence that supports extended antibiotic regimes. REVIEW REGISTRATION: Systematic review registration: CRD42014008839. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12883-016-0708-y) contains supplementary material, which is available to authorized users. BioMed Central 2016-09-29 /pmc/articles/PMC5043629/ /pubmed/27686962 http://dx.doi.org/10.1186/s12883-016-0708-y Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Dersch, Rick
Hottenrott, Tilman
Schmidt, Stefanie
Sommer, Harriet
Huppertz, Hans-Iko
Rauer, Sebastian
Meerpohl, Joerg J.
Efficacy and safety of pharmacological treatments for Lyme neuroborreliosis in children: a systematic review
title Efficacy and safety of pharmacological treatments for Lyme neuroborreliosis in children: a systematic review
title_full Efficacy and safety of pharmacological treatments for Lyme neuroborreliosis in children: a systematic review
title_fullStr Efficacy and safety of pharmacological treatments for Lyme neuroborreliosis in children: a systematic review
title_full_unstemmed Efficacy and safety of pharmacological treatments for Lyme neuroborreliosis in children: a systematic review
title_short Efficacy and safety of pharmacological treatments for Lyme neuroborreliosis in children: a systematic review
title_sort efficacy and safety of pharmacological treatments for lyme neuroborreliosis in children: a systematic review
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5043629/
https://www.ncbi.nlm.nih.gov/pubmed/27686962
http://dx.doi.org/10.1186/s12883-016-0708-y
work_keys_str_mv AT derschrick efficacyandsafetyofpharmacologicaltreatmentsforlymeneuroborreliosisinchildrenasystematicreview
AT hottenrotttilman efficacyandsafetyofpharmacologicaltreatmentsforlymeneuroborreliosisinchildrenasystematicreview
AT schmidtstefanie efficacyandsafetyofpharmacologicaltreatmentsforlymeneuroborreliosisinchildrenasystematicreview
AT sommerharriet efficacyandsafetyofpharmacologicaltreatmentsforlymeneuroborreliosisinchildrenasystematicreview
AT huppertzhansiko efficacyandsafetyofpharmacologicaltreatmentsforlymeneuroborreliosisinchildrenasystematicreview
AT rauersebastian efficacyandsafetyofpharmacologicaltreatmentsforlymeneuroborreliosisinchildrenasystematicreview
AT meerpohljoergj efficacyandsafetyofpharmacologicaltreatmentsforlymeneuroborreliosisinchildrenasystematicreview